PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34107580-0	2021	(Effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells).	lenvatinib	69-79	microRNA 23b	Homo sapiens	11-18	
34107580-1	2021	Objective: To investigate the effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells.	lenvatinib	98-108	microRNA 23b	Homo sapiens	40-47	
34107580-11	2021	In addition, EdU results showed that after miR-23b combined with lenvatinib, the positive rates of EdU staining of hepatocellular carcinoma cell line HepG2 and SMMC-7721 in the miR-23b mimic group were (32.905 +- 1.342)% and (24.811 +- 0.820)%, respectively, which were significantly lower than the control group (52.623 +- 2.441)% and (38.702 +- 1.312)% (P < 0.05).	lenvatinib	65-75	microRNA 23b	Homo sapiens	177-184	
34107580-12	2021	Conclusion: miR-23b can inhibit the proliferation, migration, invasion and vasculogenic mimicry formation, and enhance the sensitivity of lenvatinib drug in human hepatocellular carcinoma cells.	lenvatinib	138-148	microRNA 23b	Homo sapiens	12-19